<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988920</url>
  </required_header>
  <id_info>
    <org_study_id>TEN-02-401</org_study_id>
    <nct_id>NCT03988920</nct_id>
  </id_info>
  <brief_title>A Long-Term Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis</brief_title>
  <acronym>NORMALIZE</acronym>
  <official_title>A Long-Term, Open Label Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis (NORMALIZE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the ability of tenapanor alone or in combination with&#xD;
      sevelamer to achieve serum phosphorus concentration (sP) within the population reference&#xD;
      range (sP &gt;2.5 and â‰¤4.5 mg/dL) in patients with end-stage renal disease (ESRD) on dialysis&#xD;
      with hyperphosphatemia (&gt;4.5 mg/dL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who complete the TEN-02-301 study (PHREEDOM) may be eligible to enroll into&#xD;
      TEN-02-401 (NORMALIZE).&#xD;
&#xD;
      Patients from the TEN-02-301 tenapanor arm will either receive only tenapanor or be given&#xD;
      sevelamer in addition to tenapanor based on their sP. Patients from the TEN-02-301 sevelamer&#xD;
      arm will be given tenapanor in addition to their sevelamer dose and the sevelamer dose will&#xD;
      then be adjusted based on their sP following a protocol-specified dose titration schedule.&#xD;
      Patients will be monitored for safety and efficacy with in-office and telephone visits for up&#xD;
      to an additional 18 months.&#xD;
&#xD;
      Laboratory assessments will be measured at every visit (Weeks 1, 2, 3, 4, 6 and 8 and Months&#xD;
      3, 6, 9, 12, 15 and 18) using a central laboratory.&#xD;
&#xD;
      Safety assessments will be performed during the study and will include physical examinations,&#xD;
      vital signs (blood pressure and pulse), body weights, clinical laboratory evaluations,&#xD;
      12-lead electrocardiograms (ECGs), and adverse event (AE) monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieving normal serum phosphorus level</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of patients with serum phosphorus between 2.5 and 4.5 mg/dL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Tenapanor w/Sevelamer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenapanor will be administered QD or BID and sevelamer can be added to achieve desired serum phosphorus level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer w/Tenapanor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevelamer will be administered QD, BID or TID and tenapanor will be added to achieve desired serum phosphorus level and sevelamer dose will be decreased as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenapanor</intervention_name>
    <description>NHE3 Inhibitor</description>
    <arm_group_label>Sevelamer w/Tenapanor</arm_group_label>
    <arm_group_label>Tenapanor w/Sevelamer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Carbonate</intervention_name>
    <description>Phosphate binder</description>
    <arm_group_label>Sevelamer w/Tenapanor</arm_group_label>
    <arm_group_label>Tenapanor w/Sevelamer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must complete TEN-02-301 (PHREEDOM)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Schedlued for kidney transplant&#xD;
&#xD;
          2. Life expectancy &lt;12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ardelyx Site #509</name>
      <address>
        <city>Houston</city>
        <state>California</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

